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Abstract
BACKGROUND: The aim of this study is to evaluate the role of 18F-FDG PET/CT in the detection of recurrence or distant metastasis 
in patients with differentiated thyroid carcinoma (DTC) with elevated serum thyroglobulin (Tg) and negative 131I whole-body scan.
MATERIAL AND METHODS: The study included 19 patients (13 female, 6 male, average age 64 years) with DTC after total 
thyroidectomy and 131I ablation therapy that had elevated stimulated Tg and negative whole-body radioiodine scan. In all pa-
tients, standard imaging methods showed no suspicious changes. 18F-FDG PET/CT was performed after TSH stimulation with 
rhTSH or withdrawal of thyroid hormone. An evaluation of the dependence of the result of 18F-FDG PET/CT on the stimulated 
Tg levels was made accordingly. The statistical analysis was performed using Kruskal-Wallis test and ROC curves. 
RESULTS: Based on the results of the study 18F-FDG PET/CT in 6 patients, the suspicion of metastasis involved: the cervical 
lymph nodes (3 patients, ~16%) and lungs (3 patients, ~16%). The patients underwent surgery. The histopathology confirmed 
metastatic thyroid cancer in all cases. High levels of TSH-stimulated Tg (Tg from 32 to >300 ng/ml, median of 59.7 ng/ml) in pa-
tients were reported. The group of remaining 13 patients (~68%) with negative 18F-FDG PET/CT had low levels of TSH-stimulated 
Tg (Tg of from 1.76 to 10.2 ng/ml, median of 4.0 ng/ml). A particular correlation was observed between 18F-FDG PET positivity 
and stimulated Tg levels. The receiver operating characteristic curve (ROC) analysis demonstrated a stimulated Tg cut-off of 
28.5 ng/ml with 100% sensitivity and specificity. Stimulated Tg has a large and statistically significant (p<0.0001) accuracy in 
the detection of recurrence/metastasis.
CONCLUSION: 
1. 18F-FDG PET/CT is useful in the diagnosis of radioiodine-negative DTC in patients with high levels of stimulated Tg.
2. The sensitivity of 18F-FDG PET/CT increases with stimulated Tg levels. At stimulated Tg > 28.5 ng/ml, the sensitivity of the 
study reaches 100%.
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Background
Thyroglobulin (Tg) is a sensitive and specific tumor marker 
in patients with differentiated thyroid carcinoma (DTC) after total 
thyroidectomy and radioiodine treatment. Elevated serum Tg in-
dicates residual or recurrent disease (recurrence/metastasis) [1] 
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and usually has positive radioactive iodine scan (WBS, whole-body 
scan) [2, 3]. In some cases, thyroid cancer tissue does not concen-
trate I-131 [4]. Non-radioiodine avid changes are often associated 
with an aggressive clinical course [5]. In this situation it is neces-
sary to perform other tests to assist in the imaging. It has been 
shown that PET/CT using 18F-fluoro-2-deoxy-D-glucose (18F-FDG 
PET/CT) in the DTC may be useful for the detection of recurrence 
or metastases with a high degree of sensitivity, which is particularly 
useful with negative I-131 whole-body scan.
The aim of this study is to evaluate the role of 18F-FDG PET/CT 
in the detection of recurrence or distant metastasis in patients with 
differentiated thyroid carcinoma with elevated serum thyroglobulin 
and negative I-131 whole-body scan (Table 1).
Material and methods
The study included 19 patients (13 female, 6 male, average 
age 64 years) with DTC after total thyroidectomy and I-131 ablation 
therapy that had elevated stimulated Tg and negative whole-body 
radioiodine scan. In all patients, standard imaging methods (ultra-
sound neck, chest X-ray) showed no suspicious changes. PET/CT 
were performed on Siemens Biograph camera 64, 60 minutes after 
the administration of 18F-FDG activity 4 MBq/kg and after TSH stimu-
lation with rhTSH or withdrawal of thyroid hormone. An evaluation of 
the dependence of the result of 18F-FDG PET/CT on the stimulated 
Tg levels was made accordingly. The statistical analysis was per-
formed using Kruskal-Wallis test and ROC curves (Table 1). 
Results
Based on the results of the study 18F-FDG PET/CT in 6 pa-
tients, the suspicion of metastasis involved: the cervical lymph 
nodes (3 patients, ~ 16%) and lungs (3 patients, ~ 16%) (Figure 
1–6) and recommended further treatment. The patients under-
went surgery. The histopathology confirmed metastatic thyroid 
cancer in all cases. High levels of TSH-stimulated Tg (Tg from 32 
to > 300 ng/ml, median of 59.7 ng/ml) in patients with a positive 
18F-FDG PET/CT scans were reported. The group of remaining 
13 patients (~ 68%) with negative 18F-FDG PET/CT (absence 
of hypermetabolic foci) remains under further observation. 
This group of patients had low levels of TSH-stimulated Tg (Tg 
of from 1.76 to 10.2 ng/ml, median of 4.0 ng/ml) as compared 
to the patients with a positive 18F-FDG PET/CT. Tg concentra-
tion in patients with PET (+) was statistically significantly higher 
(p = 0.0006) compared with those of PET (−). The influence on 
the outcome of thyroglobulin antibody was excluded by deter-
mining the level of thyroglobulin antibody and Tg recovery test 
in all the patients.
A particular correlation was observed between 18F-FDG 
PET positivity and stimulated Tg levels. The receiver operating 
characteristic (ROC) curve analysis demonstrated a stimulated 
Tg cut-off of 28.5 ng/ml with 100% sensitivity and specificity 
(Figure 7 and 8). Stimulated Tg has a large and statistically 
significant (p < 0.0001) accuracy in the detection of recur-
rence/metastasis.
Table 1. The data and results of the patients included in the study
Patient Age, sex 
F —female 
M — male
Histological type: 
P — papillary carcinoma 
F — follicular carcinoma
pTNM Tg [ng/ml] after 
stimulation TSH
Location glucose foci in PET SUVmax Confirmation of 
cancer in  
histopathology
1 75, F F pT2N1Mx 32.0 Cervical lymph nodes Figure 1 3.73 Confirmation
2 74, F P pT3N1Mx 39.6 Cervical lymph nodes Figure 2 3.75 Confirmation
3 66, M P pT3N1Mx 66.5 Cervical lymph nodes Figure 3 7.07 Confirmation
4 54, F P pT3NxM1 > 300 Lung
Figure 4
4.27 Confirmation
5 79, F F pT3NxM1 124 Lung
Figure 5
3.25 Confirmation
6 69, F F pT2N1M1 52.9 Lung
Figure 6
8.05 Confirmation
7 59, F P pT3NoMx 7.2 Absence - No surgery
8 59, F P pT3N1Mx 3.2 Absence - No surgery
9 63, M P pT1N1Mx 5.11 Absence - No surgery
10 55, F P pT2NxMx 1.79 Absence - No surgery
11 62, F P pT3NoMx 3.05 Absence - No surgery
12 55, F P pT3N1Mx 10.2 Absence - No surgery
13 56, M P pT2N1Mx 9.2 Absence - No surgery
14 61, F P pT1NoMx 3.97 Absence - No surgery
15 77, M F pT1N1M1 10.1 Absence - No surgery
16 39, F P pT4N1M1 3.35 Absence - No surgery
17 57, F F pT1NxMx 1.76 Absence - No surgery
18 69, M P pT3NxMx 10.0 Absence - No surgery
19 65, M F pT3NxM1 3.4 Absence - No surgery
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Figure 4. 18F-FDG PET/CT revealed hypermetabolic uptakes in cervical 
lymph nodes and lungs in 6 patients
Figure 5. 18F-FDG PET/CT revealed hypermetabolic uptakes in cervical 
lymph nodes and lungs in 6 patients
Figure 6. 18F-FDG PET/CT revealed hypermetabolic uptakes in cervical 
lymph nodes and lungs in 6 patients
Figure 1. 18F-FDG PET/CT revealed hypermetabolic uptakes in cervical 
lymph nodes and lungs in 6 patients
Figure 2. 18F-FDG PET/CT revealed hypermetabolic uptakes in cervical 
lymph nodes and lungs in 6 patients
Figure 3. 18F-FDG PET/CT revealed hypermetabolic uptakes in cervical 
lymph nodes and lungs in 6 patients
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cancer. The latter group of patients (as compared to the group with 
the negative 18F-FDG PET) showed significantly greater tumor size 
(2.82 cm v. 1.72 cm) [16]. This is consistent with our observations. In 
all of our patients with positive FDG PET, the tumor size was greater 
than 2 cm — T2 feature by the TNM classification (UICC 2010).
Rivera et al. studied the histology of the metastases from 70 pa-
tients with radioactive iodine refractory but characterized by a high 
metabolic activity demonstrated in a study of 18F-FDG PET. Most 
of the changes were of more aggressive histological subtype than 
primary tumors. While comparing the histology of the primary tumor 
and its metastases, a gradual transformation of the less well-tumor 
differentiation was observed in most cases (primary tumor might 
not be FDG avid initially, whereas its metastases can be “positive 
FDG” over time) [17]. This phenomenon has been confirmed by 
molecular studies that have shown that mutations in the BRAF gene 
occur early in carcinogenesis of thyroid cancer, but mutations of 
PIK3CA and AKT1 are not to be found in primary cancers but in 
the metastases or recurrent cancers [18].
18F-FDG PET/CT scans can be applied not only to detect radioi-
odine-negative recurrences or metastases [19, 20], or to obtain in-
formation on the biology of metastases, but also to obtain prognos-
tic information. Many studies have shown that the results of 18F-FDG 
PET correlate with overall survival [9, 10, 21]. Both positive 18F-FDG 
PET in persistent/recurrent disease and a number of “FDG-pos-
itive metastases” are prognostic factors for survival [22, 10]. 
Patients with positive FDG-avid disease isolated to the regional 
lymph nodes had a low likelihood of death due to thyroid cancer 
(5-year survival of 91%) compared to 32% (p = 0.0033) for those 
with disease outside the regional lymph nodes [22]. Patients with 
SUV max greater than 10 respond less favorably to the radioiodine 
therapy and have a higher mortality rate in the observation of 3 years, 
as compared to patients without the FDG uptake [22, 23]. 
This information can be useful to justify the decision on the systemic 
treatment of patients with radioiodine-negative metastases and 
prognosis that patients can reach the maximum benefit from 
this treatment. In our study, all patients with positive foci of FDG 
PET underwent surgical treatment, which was followed by the 
observation of satisfactory levels of Tg.
FDG-PET is not sensitive enough to detect small (subcentim-
eter) metastases, as it is common in metastatic papillary thyroid 
carcinoma, and should therefore be used in conjunction with 
computed tomography (CT) imaging. In 2007, Shammas et al. 
evaluated the sensitivity and specificity of 18F-FDG PET fused 
with CT, respectively 68.4% and 82.4% in 59 patients with radio-
iodine-negative, thyroglobulin-positive recurrent DTC [24]. Other 
studies have shown the sensitivity of 70–95% and a specificity 
of 77–100% [7, 8]. In our study, the sensitivity of FDG-PET in the 
detection of metastases is slightly lower than in previous reports. 
The differences may be due to patient selection. We qualified for 
the FDG-PET patients with relatively low levels of stimulated Tg 
(from 1.76 ng/ml), as compared to other works, where qualified 
patients had a significantly higher concentrations of stimulated Tg 
(even > 10 ng/ml). 
Dietlein et al. also indicated that the degree of FDG uptake can 
vary in different organs and is the highest in the case of metasta-
sis to the lymph nodes in the neck, and the lowest in the case of 
small (less than 1 cm) lung metastases [25]. In our work we have 
not identified any dependence between the average SUV max. 
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Figure 7. The ROC curve for stimulated Tg in the detection of 
recurrence/metastasis in PET
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Figure 8. Stimulated Tg levels in PET (–) and PET (+). Logarithmic scale
Discussion
The first observations of fluorodeoxyglucose uptake in meta-
static DTC were published more than 20 years ago [6]. Currently, 
PET/CT using 18F-FDG is an increasingly useful tool in the detection 
of radioiodine-negative DTC [7–10].
The BRAF mutation, frequent in papillary thyroid carcinoma, 
leads to a reduced expression of sodium-iodine symporter (NIS) 
and increased expression of glucose transporter type 1 (GLUT1). 
Therefore, 18F-FDG uptake indicates a low degree of differentiation 
and more aggressive tumor biology [11]. A lower probability of find-
ing an increased metabolism of 18F-FDG in radioiodine-positive DTC 
[12] was confirmed, in contrast to the radioiodine-negative lesions, 
which positively correlated with result of 18F-FDG PET [7, 13, 14]. 
This correlation, known as the “flip-flop” phenomenon, has been 
also observed in our study [15].
Esterva et al. examined patients with DTC, elevated serum Tg 
and negative WBS after total thyroidectomy and I-131 ablation who 
underwent 18F-FDG PET. The authors found a positive result in 32 
of the 39 patients with confirmed metastatic or recurrent thyroid 
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and the location of metastases (lung vs. nodes), but no material 
from our patients with small lung metastases was available to us.
TSH stimulates 18F-FDG uptake by DTC cells [26]. TSH stimula-
tion with rhTSH or withdrawal of exogenous thyroxin improves the 
sensitivity of PET [26–28]. It should be noted, however, that in a large 
multicenter study only 6% of the treatment planning was changed 
after identified FDG-avid lesions with rhTSH stimulation, as com-
pared to studies with no stimulated FDG [28].
False positive results are an important issue. They can be caused 
by infections, granulomatous diseases (sarcoidosis) or postoperative 
inflammation in the changes that can coexist with thyroid cancer. 
False-positive results are reported in 11–25% of cases 18F-FDG PET 
[29, 30]. Therefore, the nature of the suspected malicious “FDG 
positive changes,” should be confirmed prior to further treatment 
of the disease. No false-positive results were observed in our study 
(all cases positive FDG PET changes were surgically removed and 
histologically confirmed as metastatic cancer). No false-positive 
results can thus occur in a relatively small group of patients studied.
The whole-body scintigraphy is not routinely performed to 
monitor disease remission in patients with DTC, and is displaced 
by the same concentration of Tg and neck ultrasound, because 
the chance of detecting radioiodine avidity recurrence without Tg 
increase is small. The criterion for the maintenance of remission 
after primary treatment is a negative ultrasound neck and the con-
centration of rhTSH-stimulated Tg below 1 ng/ml, in the absence of 
other feature of persistent or recurrent cancer, and in the absence 
of interfering factors, notably anti Tg. Scintigraphy using I-131 
is performed with an increase of concentrations of Tg to search 
for recurrent or metastatic foci DTC.
In the clinical situation, where the increase of Tg levels is not 
accompanied by the detection of lesions in conventional imaging 
studies, or the whole body iodine scintigraphy, the application of 
18F-FDG PET/CT for the location of recurrence and metastasis of 
DTC is increasingly used.
Due to the high cost of PET/CT, it should be determined first at 
what concentrations of Tg we can expect positive results of PET.
In 2001, Schlüter et al. found that the test 18F-FDG PET was the 
most promising at the concentrations of stimulated Tg > 10 ng/ml 
(TSH ≥ 30 μIU/ml). The authors reported that the true positive 
scans 18F-FDG PET were positively correlated with increasing 
concentrations of Tg and were respectively 11%, 50% and 93% in 
patients with Tg < 10, 10–20 and >100 ng/ml [31]. 
In 2005, an assessment of imaging with 18F-FDG PET in 54 
patients with radioiodine-negative DTC, suspected of thyroid cancer 
recurrence because of elevated serum-stimulated Tg > 2 ng/ml 
(TSH ≥ 30 μIU/ml). During the PET patients received a full substitu-
tion of thyroid hormones. The presence of foci of increased glucose 
metabolism were found in 25/54 patients (46.29%) at concentra-
tions of unstimulated Tg higher than 10 ng/ml [33].
The cut-off point of stimulated Tg > 10 ng/ml was then included 
in the American guidelines ATA (American Thyroid Association) in 
2009 as a recommendation for the implementation of 18F-FDG PET 
in patients with DTC and negative I-131 WBS [34].
In 2012, Polish authors reported the results of their study of 44 
patients with DTC, Tg (+), WBS (−), indicating that the positive 
results of PET/CT using 18F-FDG activity 5 MBq/kg was achieved in 
18/44 patients (40.9%), with the concentrations of endogenous or 
exogenous stimulated Tg in excess of 30 ng/ml [35]. 
Additionally, Turkish authors in their study of 105 patients with 
DTC, negative WBS and elevated concentrations of Tg, published 
in Clinical Nuclear Medicine in 2012, reported 69 true-positive, 20 
true-negative, 6 false-positive and 10 false-negative results of FDG 
PET/CT. A significant correlation was found between the positivity 
of PET and the high Tg levels (p = 0.0001). The ROC curve analy-
sis demonstrated a Tg cut-off of 1.9 ng/ml under thyroid-stimulating 
hormone suppression, 38.2 ng/ml with thyroid-stimulating hormone 
stimulation [36].
In 2013, Van Dijk et al. [37] presented a study on 52 patients with 
DTC, Tg (+) during thyroxine withdrawal, who underwent FDG 
PET within three months after the negative posttherapeutic WBS. 
Additional tumor localization has been showed in 17% of patients, 
leading to a change in the clinical management in 13%. A clinically 
useful Tg cut-off value was not found, however 90% of positive 
FDG-PET scans occurred in patients with endogenously stimulated 
Tg > 2.00 ng/ml. At Tg-off cut-off value 38 ng/ml, the sensitivity and 
specificity were 67% and 95 %, and the area under the ROC curve 
was 0.82 (p < 0.01).
Assessing scans in 60 patients, the Korean authors [38] found 
that FDG PET/CT was useful in the detection and localization of 
recurrent thyroid cancer in patients with negative diagnostic WBS 
and stimulated Tg greater than 20 ng/ml or with a high anti-TgAb 
titer (> 70 IU/ml). In contrast, FDG PET/CT provides little addi-
tional information when stimulated Tg concentration was less than 
5 ng/ml. In our study, we obtained the stimulated Tg cut-off of 
28.5 ng/ml, while the sensitivity of 18F-FDG PET/CT was 100%.
Also in 2013 Giovanella et al. [39] published a report, which 
evaluated the relationship between Tg levels, Tg doubling time 
(Tg-DT) under TSH suppression by levothyroxine treatment and 
the diagnostic usefulness of 18F-FDG PET/CT in the detection 
of recurrence in 102 patients with DTC and WBS (−). Higher 
concentrations of Tg were reported in patients with positive FDG 
PET/CT scan (median 6.7 ng/ml, range 0.7–73.6 ng/ml) than 
in patients with negative scan (median 1.8 ng/ml, range 0.5– 
–4.9 ng/ml, p < 0.001). In 43 (88%) of 49 patients with true-positive 
FDG PET/CT scan, was observed Tg> 5.5 ng/ml, in contrast to the 
31 (74%) of 42 patients with true-negative results FDG PET/CT, where 
Tg levels were ≤ 5.5 ng/ml. A Tg doubling time (Tg-DT) < 1 year 
was found in 46 of 49 patients (94%) with true-positive FDG PET/CT 
scan. In contrast, in 40 of 42 patients (95%) of the true-negative 
scans Tg-DT had a stable or increased > 1 year. The accuracy 
of FDG PET/CT was significantly increased when the serum Tg 
level was greater than 5.5 ng/ml during levothyroxine treatment or 
when Tg-DT occurred in less than 12 months, independently of the 
absolute value. In our study, we assessed the relationship between 
stimulated Tg levels and FDG PET, but also retrospectively found 
Tg-DT < 1 year in 5 (83%) of 6 patients with PET FDG (+) and Tg-DT 
a stable or > 1 year of 12 (86%) of 14 patients with FDG PET (−).
In 2012, Leboulleux et al. [40] proposed FDG PET/CT as the 
preferred over empiric WBS in DTC patients who had suspected 
recurrence based on elevated serum Tg or Tg-Ab after a normal 
postablation WBS. The sensitivity of PET/CT in the detection of 
metastatic lesions was 88–97%, compared to 16–22% for the WBS. 
The sensitivity of 18F-FDG PET depends on the number of 
cancer cells correlated with serum Tg and the rate of glucose me-
tabolism dependent on the malignancy of the tumor. The second 
parameter is the most likely factor in the differences in the sensitivity 
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of PET in patients with DTC with elevated concentrations of Tg. 
Undoubtedly, the existing achievements and new methods to be 
developed in the future will help explain the above differences and 
make the optimal use of imaging technique 18F-FDG PET in pa-
tients with recurrent or metastasis DTC possible.
Conclusions
1.  18F-FDG PET/CT is useful in the diagnosis of radioiodine-ne-
gative DTC in patients with high levels of stimulated Tg.
2.  The sensitivity of 18F-FDG PET/CT increases with stimulated 
Tg levels. At stimulated Tg > 28.5 ng/ml, the sensitivity of the 
study reaches 100%.
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